LeMaitre Vascular (NASDAQ:LMAT) Cut to Hold at Wall Street Zen

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages also recently weighed in on LMAT. Roth Capital reaffirmed a “buy” rating and set a $108.00 price objective on shares of LeMaitre Vascular in a research report on Wednesday, November 5th. Barrington Research restated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Wells Fargo & Company cut their price objective on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research report on Friday, November 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of LeMaitre Vascular in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average target price of $100.20.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $84.53 on Friday. The company has a market cap of $1.92 billion, a PE ratio of 36.44, a P/E/G ratio of 2.12 and a beta of 0.68. The firm’s 50 day moving average price is $86.88 and its 200-day moving average price is $87.06. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.45 and a current ratio of 13.58. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company had revenue of $61.05 million during the quarter, compared to analyst estimates of $62.18 million. During the same quarter in the prior year, the business earned $0.49 earnings per share. LeMaitre Vascular’s revenue was up 11.4% on a year-over-year basis. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. Sell-side analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Institutional Investors Weigh In On LeMaitre Vascular

A number of large investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. increased its position in shares of LeMaitre Vascular by 3.0% in the 2nd quarter. Advisors Asset Management Inc. now owns 4,111 shares of the medical instruments supplier’s stock valued at $341,000 after acquiring an additional 118 shares during the period. Johnson Investment Counsel Inc. increased its holdings in shares of LeMaitre Vascular by 0.5% in the third quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after purchasing an additional 153 shares during the period. Federated Hermes Inc. raised its stake in shares of LeMaitre Vascular by 0.4% in the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after purchasing an additional 155 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of LeMaitre Vascular by 2.2% during the third quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock worth $630,000 after purchasing an additional 158 shares during the period. Finally, Illinois Municipal Retirement Fund boosted its position in LeMaitre Vascular by 1.6% in the third quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock valued at $967,000 after buying an additional 171 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.